Laparoscopic Approach to Cervical Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: LACC001, NCI-2014-01556, NCT00614211
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: LACC001, NCI-2014-01556, NCT00614211
Three Different Radiation Therapy Regimens in Treating Patients with Limited-Stage Small Cell Lung Cancer Receiving Cisplatin or Carboplatin and Etoposide
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CALGB 30610/RTOG 0538, NCI-2009-00470, CDR0000588879, RTOG 0538, CALGB-30610, NCT00632853
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CALGB 30610/RTOG 0538, NCI-2009-00470, CDR0000588879, RTOG 0538, CALGB-30610, NCT00632853
Sorafenib Long Term Extension Program (STEP)
Status: Active
Phase: Phase III
Type: Treatment
Age: 16 and over
Trial IDs: 12311, NCI-2012-01207, 2007-002604-17, NCT00625378
Phase: Phase III
Type: Treatment
Age: 16 and over
Trial IDs: 12311, NCI-2012-01207, 2007-002604-17, NCT00625378
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System
Status: Temporarily closed
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under at the time of definitive surgery
Trial IDs: ACNS0333, NCI-2009-00337, CDR0000592812, COG-ACNS0333, NCT00653068
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under at the time of definitive surgery
Trial IDs: ACNS0333, NCI-2009-00337, CDR0000592812, COG-ACNS0333, NCT00653068
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients with Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: GOG-0225, NCI-2009-00595, CDR0000594600, NCT00719303
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: GOG-0225, NCI-2009-00595, CDR0000594600, NCT00719303
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: LF-0208, NCI-2009-01425, NCT00706862
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: LF-0208, NCI-2009-01425, NCT00706862
Efficacy of Adjuvant Mitotane Treatment (ADIUVO)
Status: Active
Phase: Phase III
Type: Treatment
Age: Over 18
Trial IDs: EudraCT 2007-007262-38, NCI-2014-00699, NCT00777244
Phase: Phase III
Type: Treatment
Age: Over 18
Trial IDs: EudraCT 2007-007262-38, NCI-2014-00699, NCT00777244
Health Education Materials With or Without a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Educational/Counseling/Training
Age: 18 and over
Trial IDs: CO21, NCI-2015-01662, CAN-NCIC-CO21, CDR0000629834, NCT00819208
Phase: Phase III
Type: Biomarker/Laboratory analysis, Educational/Counseling/Training
Age: 18 and over
Trial IDs: CO21, NCI-2015-01662, CAN-NCIC-CO21, CDR0000629834, NCT00819208
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: AB04030, NCI-2011-02630, NCT00812240
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: AB04030, NCI-2011-02630, NCT00812240
A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: AB06006, NCI-2010-01207, NCT00814073
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: AB06006, NCI-2010-01207, NCT00814073
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Status: Active
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: 20070782, NCI-2010-00172, NCT00858364
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: 20070782, NCI-2010-00172, NCT00858364
Radiation Therapy or Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed Anaplastic Glioma or Low Grade Glioma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: N0577, NCI-2011-01915, CDR0000640442, EORTC-26081-22086, EudraCT-2008-007295-14, NCCTG-N0577, NCT00887146
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: N0577, NCI-2011-01915, CDR0000640442, EORTC-26081-22086, EudraCT-2008-007295-14, NCCTG-N0577, NCT00887146
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
Status: Active
Phase: Phase III
Type: Diagnostic
Age: 18 and over
Trial IDs: AMI-2008-01, NCI-2014-02587, NCT00882609
Phase: Phase III
Type: Diagnostic
Age: 18 and over
Trial IDs: AMI-2008-01, NCI-2014-02587, NCT00882609
Azacitidine in Preventing Relapse in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome Previously Treated with Donor Stem Cell Transplant
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 75
Trial IDs: 2008-0503, NCI-2012-01259, NCI-2009-01513, NCT00887068
Phase: Phase III
Type: Treatment
Age: 18 to 75
Trial IDs: 2008-0503, NCI-2012-01259, NCI-2009-01513, NCT00887068
TK008: Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TK008, NCI-2011-03649, 2009-012973-37, NCT00914628
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TK008, NCI-2011-03649, 2009-012973-37, NCT00914628
Radiation Therapy with or without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: RTOG-0920, NCI-2011-00878, CDR0000651536, NCT01311063, NCT00956007
Phase: Phase III
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: RTOG-0920, NCI-2011-00878, CDR0000651536, NCT01311063, NCT00956007
Chemotherapy and Pelvic Radiation Therapy with or without Additional Chemotherapy in Treating Patients with High-Risk Early-Stage Cervical Cancer after Radical Hysterectomy
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: RTOG 0724/GOG-0724, NCI-2011-01973, CDR0000654709, GOG-0724, RTOG-0724, NCT00980954
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: RTOG 0724/GOG-0724, NCI-2011-01973, CDR0000654709, GOG-0724, RTOG-0724, NCT00980954
Risk-Based Therapy in Treating Younger Patients with Newly Diagnosed Liver Cancer
Status: Active
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Age: 21 and under
Trial IDs: AHEP0731, NCI-2011-01975, CDR0000654889, COG-AHEP0731, NCT02265692, NCT00980460
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Age: 21 and under
Trial IDs: AHEP0731, NCI-2011-01975, CDR0000654889, COG-AHEP0731, NCT02265692, NCT00980460
Neurotropic Melanoma of the Head and Neck
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TROG 08.09, NCI-2015-00466, 2009/039, ACTRN12610000478011, NCT00975520
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TROG 08.09, NCI-2015-00466, 2009/039, ACTRN12610000478011, NCT00975520
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG-0848, NCI-2011-01987, CDR0000659092, NCT01013649
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG-0848, NCI-2011-01987, CDR0000659092, NCT01013649
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Temporarily closed
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: E2906, NCI-2011-01992, CDR0000659585, ECOG-E2906, NCT01041703
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: E2906, NCI-2011-01992, CDR0000659585, ECOG-E2906, NCT01041703
Risk-Adapted Therapy in Treating Young Patients with Mature B-Cell Lymphoma or Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 0 to 21
Trial IDs: SJBC3, NCI-2011-01251, NCI-2010-00129, NCT01046825
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 0 to 21
Trial IDs: SJBC3, NCI-2011-01251, NCI-2010-00129, NCT01046825
Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 110918, NCI-2015-00005, NCT01077518
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 110918, NCI-2015-00005, NCT01077518
Everolimus in Treating Patients with Kidney Cancer Who Have Undergone Surgery
Status: Active
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: S0931, NCI-2011-02028, CDR0000668388, SWOG-S0931, NCT01120249
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: S0931, NCI-2011-02028, CDR0000668388, SWOG-S0931, NCT01120249
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ACNS0831, NCI-2011-02029, CDR0000668560, COG-ACNS0831, NCT01096368
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ACNS0831, NCI-2011-02029, CDR0000668560, COG-ACNS0831, NCT01096368
No hay comentarios:
Publicar un comentario